FDA’s Zuckerman Warns Against Inventor Involvement In Clinical Trials
This article was originally published in The Gray Sheet
Executive Summary
Inventors should have minimal involvement in early clinical trials of their own technology, according to FDA's top cardiovascular device reviewer
You may also be interested in...
MedPAC Wants Congress To Require Sunshine For Doc/Device Maker Ties
The Medicare Payment Advisory Commission (MedPAC) is recommending to Congress that health care providers be required to report their financial relationships with industry on a public Web site
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.